Hepa Wash
Medical technology company (Munich) developing an extracorporeal multiorgan blood purification therapy. The method uses an albumin-enriched recirculating dialysate with controlled pH adjustments to enable removal of protein-bound and water-soluble toxins, fluid-mediated CO2 removal and targeted acid–base correction. The company performs in-house device development, production and quality assurance in Germany and maintains ISO 13485 and MDR/CE certifications. Patient- and clinician-facing materials indicate use in intensive care indications including multiorgan failure and sepsis.
Industries
Nr. of Employees
small (1-50)
Hepa Wash
Agnes-Pockels-Bogen 1, 80992 München, Germany
Products
Integrated multiorgan extracorporeal blood purification platform
Device platform that combines renal replacement, albumin-based toxin removal and fluid-mediated CO2 removal with integrated dialysate regeneration and adjustable pH control; supports continuous and intermittent therapy modes for critical care settings.
Extended-duration continuous extracorporeal therapy configuration
Platform variant engineered to support prolonged continuous treatments (documented support for therapy durations up to 72 hours) for sustained renal replacement and multiorgan support.
Integrated multiorgan extracorporeal blood purification platform
Device platform that combines renal replacement, albumin-based toxin removal and fluid-mediated CO2 removal with integrated dialysate regeneration and adjustable pH control; supports continuous and intermittent therapy modes for critical care settings.
Extended-duration continuous extracorporeal therapy configuration
Platform variant engineered to support prolonged continuous treatments (documented support for therapy durations up to 72 hours) for sustained renal replacement and multiorgan support.
Services
Round-the-clock hotlines and local application consultants providing clinical setup assistance and technical troubleshooting, with on-site service and repairs.
Hands-on and case-based workshops, master classes and user group meetings to train clinicians on device operation, indications and practical case discussions.
Curated literature service providing access to in vitro studies, clinical reports, conference abstracts and downloadable scientific materials related to the therapy.
Distribution of brochures, technical posters, videos and image assets for clinical, academic and media use.
Round-the-clock hotlines and local application consultants providing clinical setup assistance and technical troubleshooting, with on-site service and repairs.
Hands-on and case-based workshops, master classes and user group meetings to train clinicians on device operation, indications and practical case discussions.
Curated literature service providing access to in vitro studies, clinical reports, conference abstracts and downloadable scientific materials related to the therapy.
Distribution of brochures, technical posters, videos and image assets for clinical, academic and media use.
Expertise Areas
- Extracorporeal organ support for combined renal, hepatic and pulmonary dysfunction
- Acid–base management and fluid-mediated CO2 removal in extracorporeal circuits
- Albumin-based dialysate regeneration and toxin separation by pH cycling
- Critical care indications: sepsis and multiorgan failure management
Key Technologies
- Albumin-enriched dialysate with controlled chemical regeneration
- Dialysate recirculation with pH-cycling regeneration
- Fluid-mediated extracorporeal CO2 removal via pH/bicarbonate manipulation
- Low-blood-flow extracorporeal operation (≈100–500 mL/min)
News & Updates
Company received two Red Dot design awards for its next-generation device in 2025.
Company presented a new generation of its extracorporeal blood purification system at a national intensive care congress in late 2024.
Press announcements in 2024–2025 describe a financial and shareholder restructuring and reorganization of the company.
First user group meeting with clinicians from multiple hospitals held in May 2023.
Coverage and advertorials relating to clinical symposia and advances in multiorgan-support therapy.
Two international Red Dot design awards for the company's next-generation therapy platform.
Company received two Red Dot design awards for its next-generation device in 2025.
Company presented a new generation of its extracorporeal blood purification system at a national intensive care congress in late 2024.
Press announcements in 2024–2025 describe a financial and shareholder restructuring and reorganization of the company.
First user group meeting with clinicians from multiple hospitals held in May 2023.
Coverage and advertorials relating to clinical symposia and advances in multiorgan-support therapy.
Two international Red Dot design awards for the company's next-generation therapy platform.